Ignite Creation Date:
2024-05-05 @ 5:30 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00479557
Status:
COMPLETED
Last Update Posted:
2016-01-01
First Post:
2007-05-24
Brief Title:
Study Evaluating Safety Tolerability And Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimers Disease
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
A Phase Iia Multicenter Randomized Third-party Unblinded Adjuvant And Placebo-controlled Multiple Ascending Dose Safety Tolerability And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimers Disease
Status:
COMPLETED
Status Verified Date:
2015-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To assess the safety tolerability and immunogenicity of ACC-001 an investigational active immunization in patients with mild to moderate Alzheimers disease
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2006-002061-39 | EUDRACT_NUMBER | Alias Study Number | None |
| B2571004 | OTHER | None | None |